NovaBridge Biosciences (0VY) Stock Overview

A biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. More details

0VY fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Analysts in good agreement that stock price will rise by 396.9%

Risk Analysis

Shareholders have been substantially diluted in the past year

Earnings are forecast to decline by an average of 20.1% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

0VY Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW473,006 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

473,006 investors already sharing narratives

View all narratives

NovaBridge Biosciences Competitors

Price History & Performance

Summary of share price highs, lows and changes for NovaBridge Biosciences
Historical stock prices
Current Share Price	US$1.51
52 Week High	US$5.60
52 Week Low	US$1.25
Beta	1.45
1 Month Change	6.34%
3 Month Change	-24.12%
1 Year Change	2.72%
3 Year Change	-39.11%
5 Year Change	-97.71%
Change since IPO	-86.98%

Recent updates

Shareholder Returns

	0VY	DE Biotechs	DE Market
7D	-3.8%	0.8%	1.2%
1Y	2.7%	4.5%	0.7%

Return vs Industry: 0VY underperformed the German Biotechs industry which returned 4.6% over the past year.

Return vs Market: 0VY exceeded the German Market which returned 0.8% over the past year.

Price Volatility

Is 0VY's price volatile compared to industry and market?
0VY volatility
0VY Average Weekly Movement	9.8%
Biotechs Industry Average Movement	7.1%
Market Average Movement	5.4%
10% most volatile stocks in DE Market	12.8%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: 0VY's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 0VY's weekly volatility has decreased from 17% to 10% over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2014	30	Srishti Gupta	novabridge.com

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer.

NovaBridge Biosciences Fundamentals Summary

How do NovaBridge Biosciences's earnings and revenue compare to its market cap?
0VY fundamental statistics
Market cap	€176.74m
Earnings (TTM)	-€77.15m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-2.1x

P/E Ratio

Is 0VY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0VY income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$88.34m
Earnings	-US$88.34m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.76
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 0VY perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/29 08:43
End of Day Share Price	2026/07/29 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NovaBridge Biosciences is covered by 17 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Bo Li	BofA Global Research
Kumaraguru Raja	Brookline Capital Markets
Ziyu He	China International Capital Corporation Limited

NovaBridge Biosciences (0VY) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

NovaBridge Biosciences Competitors

2invest

Formycon

Dextech Medical

Genetic Analysis

Price History & Performance

Recent News & Updates

NovaBridge Biosciences, Annual General Meeting, Sep 08, 2026

Novabridge Biosciences Announces Appointment of Srishti Gupta as Member of the Board of Directors, Effective July 1, 2026

Novabridge Biosciences Receives Fda Fast Track Designation for Givastomig in First-Line Her2-Negative Metastatic Gastric Cancer

Less than half of directors are independent

Novabridge Biosciences Appoints Mark Hagler as President and Chief Commercial Officer

NovaBridge Biosciences Announces Productive FDA Type B Meeting On Potential Accelerated Approval Pathway For Givastomig In Gastric Cancer

Recent updates

NovaBridge Biosciences, Annual General Meeting, Sep 08, 2026

Novabridge Biosciences Announces Appointment of Srishti Gupta as Member of the Board of Directors, Effective July 1, 2026

Novabridge Biosciences Receives Fda Fast Track Designation for Givastomig in First-Line Her2-Negative Metastatic Gastric Cancer

Less than half of directors are independent

Novabridge Biosciences Appoints Mark Hagler as President and Chief Commercial Officer

NovaBridge Biosciences Announces Productive FDA Type B Meeting On Potential Accelerated Approval Pathway For Givastomig In Gastric Cancer

Novabridge Biosciences Announces Positive Results from Vis-101 Phase 2A Wet Amd Study

NovaBridge Biosciences Appoints Emmett T. Cunningham, Jr. as Vice Chairman of the Board and Member of the Research and Development Committee

NovaBridge Biosciences Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer

NovaBridge Biosciences Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer

NovaBridge Biosciences Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO

Novabridge Biosciences Announces Presentation of Ragistomig Expanded Phase 1 Data At Esmo-Io

Novabridge Biosciences Appoints Ian Woo to Its Board of Directors

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

I-Mab Announces Acceleration of Givastomig Investment

I-Mab Announces Board Changes

I-Mab Completes Enrollment in Planned Phase 1B Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers

I-Mab has completed a Follow-on Equity Offering in the amount of $65.000001 million.

I-Mab Inc. Announces Data Based on the Results of the Dose Escalation Part of A Phase 1B Study Evaluating the Givastomig Combination as First Line Therapy

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers At Esmo Gi 2025

I-Mab to Report Q1, 2025 Results on May 15, 2025

I-Mab Announces Accelerated Givastomig Phase 1B Study Progress

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

Third quarter 2024 earnings released: US$0.25 loss per share (vs US$0.57 loss in 3Q 2023)

I-Mab Appoints Sean (Xi-Yong) Fu as Chief Executive Officer

I-Mab to Report Q3, 2024 Results on Nov 14, 2024

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

First half 2024 earnings released: US$0.19 loss per share (vs US$1.32 loss in 1H 2023)

I-Mab to Report First Half, 2024 Results on Aug 28, 2024

New minor risk - Market cap size

Insufficient new directors

I-Mab Announces Board and Committee Changes

I-Mab Appoints Phillip Dennis as Chief Medical Officer

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

Full year 2023 earnings released: CN¥16.53 loss per share (vs CN¥29.23 loss in FY 2022)

New minor risk - Financial data availability

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-Mab Announces Board Changes , Effective February 10, 2024

I-Mab and Hi-Bio Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Felzartamab, an Investigational Cd38 Antibody, for the Treatment of Primary Memorbranous Nephropathy (PMN)

I-Mab Announces Phase 1 Data of Givastomig at Esmo 2023

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1Bb Bispecific Antibody Tj-L14b Abl503

New major risk - Share price stability

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab to Report First Half, 2023 Results on Aug 17, 2023

I-Mab Announces the Appointment of Raj Kannan as Member of the Board of Directors

TRACON Pharmaceuticals, Inc. Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma

First half 2022 earnings released: CN¥12.75 loss per share (vs CN¥14.67 loss in 1H 2021)

Less than half of directors are independent

I-Mab Announces Management Changes

I-Mab Announces Executive Changes

I-Mab(NasdaqGM:IMAB) dropped from FTSE All-World Index (USD)

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab to Report First Half, 2022 Results on Aug 30, 2022

I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1Bb Bispecific Antibody TJ-CD4B in Solid Tumors in China

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin Alfa for Treatment of Pediatric Growth Hormone Deficiency

I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

I-Mab Reportedly Exploring Possible Sale Amid Takeover Interest